
Acadia (ACAD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
244.3M
Gross Profit
223.9M
91.65%
Operating Income
19.3M
7.90%
Net Income
19.0M
7.77%
EPS (Diluted)
$0.11
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
367.1M
Shareholders Equity
765.2M
Debt to Equity
0.48
Cash Flow Metrics
Operating Cash Flow
19.6M
Free Cash Flow
-78.5M
Revenue & Profitability Trend
Acadia Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 957.8M | 726.4M | 517.2M | 484.1M | 441.8M |
Cost of Goods Sold | 81.8M | 41.6M | 10.2M | 19.1M | 20.6M |
Gross Profit | 876.0M | 684.8M | 507.1M | 465.0M | 421.2M |
Gross Margin % | 91.5% | 94.3% | 98.0% | 96.0% | 95.3% |
Operating Expenses | |||||
Research & Development | 303.2M | 351.6M | 361.6M | 239.4M | 319.1M |
Selling, General & Administrative | 488.4M | 406.6M | 369.1M | 396.0M | 388.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 791.7M | 758.2M | 730.7M | 635.4M | 707.8M |
Operating Income | 84.3M | -73.4M | -223.6M | -170.4M | -286.6M |
Operating Margin % | 8.8% | -10.1% | -43.2% | -35.2% | -64.9% |
Non-Operating Items | |||||
Interest Income | 25.5M | 17.2M | 6.6M | 591.0K | 6.6M |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 148.3M | 5.1M | 3.5M | 2.3M | -997.0K |
Pre-tax Income | 258.1M | -51.0M | -213.4M | -167.5M | -281.0M |
Income Tax | 31.6M | 10.2M | 2.5M | 351.0K | 611.0K |
Effective Tax Rate % | 12.3% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | 226.5M | -61.3M | -216.0M | -167.9M | -281.6M |
Net Margin % | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% |
Key Metrics | |||||
EBITDA | -46.4M | -67.8M | -221.6M | -167.1M | -283.7M |
EPS (Basic) | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 |
EPS (Diluted) | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 |
Basic Shares Outstanding | 165717000 | 163819000 | 161683000 | 160493000 | 157331000 |
Diluted Shares Outstanding | 165717000 | 163819000 | 161683000 | 160493000 | 157331000 |
Income Statement Trend
Acadia Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 319.6M | 188.7M | 114.8M | 147.4M | 326.0M |
Short-term Investments | 436.4M | 250.2M | 302.0M | 373.3M | 305.9M |
Accounts Receivable | 98.7M | 98.3M | 62.2M | 64.4M | 48.2M |
Inventory | 21.9M | 35.8M | 6.6M | 7.9M | 9.7M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 938.3M | 616.1M | 507.9M | 617.8M | 717.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 46.6M | 51.9M | 55.6M | 58.3M | 47.3M |
Goodwill | 119.8M | 65.5M | 0 | 0 | 1.1M |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 78.9M | 10.9M | 18.3M | 16.0M | 7.4M |
Total Non-Current Assets | 249.4M | 132.8M | 79.9M | 82.3M | 65.0M |
Total Assets | 1.2B | 749.0M | 587.8M | 700.1M | 782.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 16.2M | 17.5M | 12.7M | 6.9M | 8.5M |
Short-term Debt | 10.0M | 9.4M | 9.3M | 8.3M | 5.1M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 394.9M | 254.3M | 125.6M | 96.1M | 106.0M |
Non-Current Liabilities | |||||
Long-term Debt | 42.0M | 47.8M | 52.7M | 56.1M | 44.5M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 18.1M | 15.1M | 9.1M | 7.0M | 5.2M |
Total Non-Current Liabilities | 60.1M | 62.9M | 61.8M | 63.2M | 49.6M |
Total Liabilities | 455.0M | 317.2M | 187.4M | 159.2M | 155.6M |
Equity | |||||
Common Stock | 16.0K | 16.0K | 16.0K | 16.0K | 16.0K |
Retained Earnings | -2.2B | -2.4B | -2.4B | -2.2B | -2.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 732.8M | 431.8M | 400.4M | 540.9M | 627.0M |
Key Metrics | |||||
Total Debt | 52.0M | 57.2M | 62.0M | 64.4M | 49.5M |
Working Capital | 543.4M | 361.9M | 382.3M | 521.8M | 611.6M |
Balance Sheet Composition
Acadia Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 226.5M | -61.3M | -216.0M | -167.9M | -281.6M |
Depreciation & Amortization | 15.9M | 5.6M | 2.0M | 3.3M | 2.9M |
Stock-Based Compensation | 67.0M | 66.4M | 68.2M | 63.6M | 84.4M |
Working Capital Changes | -50.3M | -57.3M | 11.2M | -18.2M | -4.4M |
Operating Cash Flow | 259.1M | -46.7M | -134.6M | -119.1M | -154.4M |
Investing Activities | |||||
Capital Expenditures | -523.0K | -50.0K | 0 | -1.1M | -7.6M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -505.1M | -370.0M | -363.2M | -492.8M | -339.9M |
Investment Sales | 328.6M | 442.0M | 436.4M | 422.8M | 540.0M |
Investing Cash Flow | -30.5M | 72.0M | 73.2M | -71.1M | 192.5M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 6.8M | 25.1M | 8.2M | 18.2M | 81.0M |
Free Cash Flow | 157.2M | -23.3M | -114.0M | -126.8M | -143.8M |
Net Change in Cash | 235.4M | 50.5M | -53.1M | -172.0M | 119.1M |
Cash Flow Trend
Acadia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.64
Forward P/E
30.23
Price to Book
5.08
Price to Sales
4.10
PEG Ratio
-0.93
Profitability Ratios
Profit Margin
21.80%
Operating Margin
12.24%
Return on Equity
33.18%
Return on Assets
5.28%
Financial Health
Current Ratio
2.91
Debt to Equity
6.85
Beta
0.70
Per Share Data
EPS (TTM)
$1.33
Book Value per Share
$4.88
Revenue per Share
$6.11
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
acad | 4.2B | 18.64 | 5.08 | 33.18% | 21.80% | 6.85 |
Vertex | 100.2B | 27.77 | 5.83 | 22.77% | 31.86% | 8.89 |
Regeneron | 62.9B | 14.95 | 2.06 | 15.34% | 31.37% | 9.04 |
BridgeBio Pharma | 9.4B | -16.98 | -5.24 | 36.76% | 98.25% | -1.04 |
Madrigal | 8.5B | -17.67 | 12.12 | -36.30% | -54.68% | 17.81 |
Blueprint Medicines | 8.4B | -120.99 | 24.43 | -47.71% | -27.70% | 208.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.